Sonelokimab Interleukin-17A and -F nanobody Treatment of moderate to severe psoriasis Treatment of hidradenitis suppurativa
Research output: Contribution to journal › Journal article › Research › peer-review
Psoriasis is a common, chronic inflammatory disease characterized by sustained inflammation and hyperproliferation of epidermal keratinocytes. With the establishment of the interleukin (IL)-17/IL-23 pathway as a principal player in the etiopathogenesis of psoriasis, and the subsequent development of anti-IL-17/IL-23 biologics, targeted treatment for psoriasis has significantly improved within the past decade. Currently, 4 IL-17 inhibitors are approved for the treatment of moderate to severe plaque psoriasis in adults-secukinumab, ixekizumab, brodalumab and bimekizumab-all of which are monoclonal antibodies. In this scoping review article, we present the current literature on sonelokimab, a novel anti-IL-17A/F nanobody for the treatment of moderate to severe psoriasis.
Original language | English |
---|---|
Journal | Drugs of the Future |
Volume | 47 |
Issue number | 8 |
Pages (from-to) | 567-573 |
Number of pages | 7 |
ISSN | 0377-8282 |
DOIs | |
Publication status | Published - Aug 2022 |
- IL-17, Monoclonal antibody, Nanobody, Psoriasis, Sonelokimab, M-1095, SEVERE PLAQUE PSORIASIS, DOUBLE-BLIND, MULTICENTER, EFFICACY, SAFETY, BIMEKIZUMAB, MECHANISMS, FAMILY, SHARK
Research areas
ID: 317739663